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To find mRNAs whose expression differs between thyroid follicular adenomas and carcinomas, a high-throughput analysis of mRNAs
in these two tumours was performed. This method, named high-throughput differential screening by serial analysis of gene expression
(HDSS), combines a modified method of serial analysis of gene expression (SAGE) and real-time quantitative reverse transcription
polymerase chain reaction (RT–PCR). A total of 40 candidate tag sequences that showed extremely different expression levels
between a follicular carcinoma and a follicular adenoma in the SAGE analysis were analysed by real-time quantitative RT–PCR, using
RNAs from an additional four typical follicular carcinomas and adenomas. One sequence tag that represents trefoil factor 3 (TFF3)
mRNA showed a clear difference in its expression level between adenomas and carcinomas. The expression levels of TFF3 mRNA in
48 follicular adenomas and 29 follicular carcinomas were measured by real-time quantitative RT–PCR using a specific probe for TFF3.
They were significantly decreased in follicular carcinomas, especially in widely invasive types and those with evident metastases. These
results indicate that the decreased expression of TFF3 mRNA is a marker of follicular carcinomas, especially those with a high risk of
invasion or metastasis.
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Modern advances in molecular technology have given us the
chance to establish new strategies in diagnosing cancer. In order to
implement such molecular-based technology, it is crucial to
identify a distinct difference between benign and malignant cells
(Takano and Amino, 2002). Thyroid tumours are relatively
common, especially in women. They are often diagnosed by fine
needle aspiration biopsy (FNAB) as well as by ultrasonography
(Hamburger, 1994; Yokozawa et al, 1995). Cytological examination
of FNAB by a skillful pathologist who is an expert in thyroid
tumours provides the most reliable information for the diagnosis
of thyroid neoplasms. In some clinical situations, however, a more
objective method is required for exact diagnosis.
In the light of this, we developed a new method of preoperative
molecular-based diagnosis of malignant tumours, named aspira-
tion biopsy RNA diagnosis (ABRD), which utilises extracted RNAs
from leftover cells within the needle used for FNAB for reverse
transcription–polymerase chain reaction (RT–PCR) analysis
(Takano et al, 1997). For the thyroid, by detecting the specific
changes in mRNAs in malignant thyroid tissues by ABRD, an
accurate and objective diagnosis can be made in papillary,
anaplastic and medullary carcinomas and some malignant
lymphomas (Takano et al, 1998a, 1999a, 2000a).
Follicular carcinoma of the thyroid is a relatively uncommon
malignancy and it accounts for about 15% of all thyroid cancer.
One of the most difficult distinctions in thyroid pathology is the
differentiation between benign follicular adenoma and the
encapsulated low-grade follicular carcinoma called minimally
invasive carcinoma. The principal differentiating feature is
capsular invasion. Even this, however, may not be definitive,
because a slight capsular penetration can also be observed in
benign tumours. Further, both types of tumours have varying
degrees of cellular atypia, and extensive invasion into vascular
spaces is not usually observed in minimally invasive carcinomas.
Preoperative diagnosis of follicular carcinoma is even more
difficult, since the feature that separated the benign and malignant
follicular tumours is the presence of capsular invasion, which is
not possible to determine cytologically (Cooper and Schneyer,
1990).
A promising tool for solving this problem is molecular-based
diagnosis, such as ABRD. However, at present, ABRD cannot be
applied to the preoperative diagnosis of follicular carcinomas
because no mRNAs that distinguish adenomas from carcinomas
have been reported so far. By relying on 14–15 base cDNA
sequences for gene identification, serial analysis of gene expression
(SAGE) can generate a quantitative transcript profile easily, a task
currently not possible using alternative transcript imaging
technologies (Velculescu et al, 1995). Since its introduction in
1995, SAGE has been used to analyse cDNA libraries derived from
several carcinomas and its reliability has been established.
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sRecently, we established the gene expression profiles of normal
thyroids and thyroid tumours and reported some specific changes
in mRNAs in thyroid carcinomas (Takano et al, 2000b, 2001,
2002a,b; Hasegawa et al, 2002). However, even using SAGE
analysis, identification of differentially expressed mRNAs in
follicular carcinomas was still quite difficult because of the close
similarity in the gene expression of follicular adenomas and
carcinomas. To solve this problem, it is necessary to perform a
high-throughput second screening of candidate sequences,
although this is not possible by using the original protocol of
SAGE mainly because of the very short sequence tags generated.
A recent modification in the SAGE protocol can construct a gene
expression profile with 18-bp tag sequences (Ryo et al, 2000). By
using this modification, we established a combined analysis of
SAGE and real-time quantitative RT–PCR, named high-through-
put differential screening by SAGE (HDSS). In this study, by using
HDSS, we screened differentially expressed genes in a follicular
carcinoma and a follicular adenoma, and found a decreased
expression of trefoil factor 3 (TFF3) mRNA in follicular
carcinomas. Further, we measured the expression levels of TFF3
in each thyroid malignancy by real-time quantitative RT–PCR.
MATERIALS AND METHODS
Extraction of RNA from thyroid tissues
Tissue samples from 19 normal thyroid tissues in the opposite lobe
from carcinomas, nine medullary carcinomas, 10 adenomatous
goitres, 48 follicular adenomas, 29 follicular carcinomas, 25
papillary carcinomas, and five anaplastic carcinomas were
obtained by surgery after patients’ informed consent. Tumours
were classified according to the WHO histological classification of
thyroid tumours by skillful pathologists (Hedinger et al, 1989). All
tissues were frozen in liquid nitrogen immediately after resection.
Total RNA was extracted according to the method of Chomczynski
and Sacchi (1987).
Reverse transcription
Reverse transcription was performed using either 1mg of total RNA
in an RT mixture containing 50mM Tris-HCl (pH 8.3), 75mM KCl,
10mM dithiothreitol, 3mM MgCl2, 0.5mM dNTPs, 200U M-MLV
reverse transcriptase (Gibco, Gaithersburg, MD, USA), 2Uml
 1
RNase inhibitor (Takara, Shiga, Japan), and 2.5mM oligo dT
(Gibco) in a total volume of 20mla t3 7 1C for 60min.
HDSS procedures
In total, 50mg of total RNA from a follicular adenoma and a widely
invasive follicular carcinoma were used for the construction of
gene expression profiles. Modified SAGE was performed as
described previously (Ryo et al, 2000). Then thousand tags were
analysed in each sample. After analysis by PROGENEX software,
which was kindly provided by Dr Toru Wakatsuki of the National
Defense Medical College (Tokorozawa, Japan), tag sequences for
which expression differed greatly between the two tissues were
detected. According to these data, 40 18-bp sequences were
selected as 50 primers in the following analysis (Table 1): using one
of the 12 primers, CGCGCGT13VN, as the 30 primer, cDNA from
the corresponding tissue, either the follicular adenoma or the
follicular carcinoma, was amplified by real-time quantitative PCR.
By real-time quantitative PCR analysis with the ABI PRIZM 7700
Sequence Detection System using an SYBR Green PCR Master Mix
(Applied Biosystems, Warrington, UK), a 30 primer with the most
optimal amplification was selected. As shown in Figure 1 and
Table 1, a single band was observed in the PCR products of 37 of
the 40 primer sets after gel electrophoresis. The results of real-time
quantitative RT–PCR using cDNA from the two tissues and the
data of the SAGE analysis were compared. The differences in
expression levels analysed by RT–PCR agreed with the SAGE data
in 26 of the 37 sequences. With these 26 primer sets, a second
screening by real-time quantitative PCR analysis was performed
using cDNAs from four other follicular adenomas and four
follicular carcinomas (three widely invasive and one minimally
invasive).
Real-time quantitative PCR
Real-time quantitative PCR (TaqMan PCR) using the ABI PRISM
7700 Sequence Detection System was performed as described
previously (Takano et al, 1999b). In total, 1ml of the first-strand
cDNA was used in the following assay. The two primers and one
TaqMan probe used for the quantification of TFF3 and b-actin
mRNA (Ponte et al, 1984; Hauser et al, 1993) were:
TFF3F (0.5mM): 50-AATGCACCTTCTGAGGCACCT-30 (base
265–285); TFF3R (0.5mM): 50-CGTTAAGACATCAGGCTCCA-
GAT-30 (base 414–436); and TFF3-TM (10pmol): 50-FAM-
CATCTCAGCTTTTCTGTCCCTTTGCTCCC-TAMRA-30 (base
359–387); ACF (0.5mM): 50-TGGACATCCGCAAAGACCTG-30
(base 901–920); ACR (0.5mM): 50-CCGATCCACACGGAGTACTT-
30 (base1047–1066); and AC-TM (10pmol): 50-FAM-CACCAC-
CATGTACCCTGGCATTGCC-TAMRA-30 (base 947–971), respec-
tively. The conditions for the TaqMan PCR were as follows: 951C
for 10min and 40 cycles of 951C for 15s and 601C for 1min.
Recombinant pGEM Easy T-Vectors (Promega, Tokyo, Japan)
containing either TFF3 or b-actin cDNA were constructed by PCR-
cloning with the same set of primers used in TaqMan PCR and
were used as standard samples.
In situ hybridisation
In situ hybridisation was performed essentially as described
previously (Takano et al, 1998b). In total, 7-mm-thick frozen
sections from a follicular adenoma were used in this study.
Digoxigenin-labelled single-strand RNA probes were prepared
using a DIG RNA labelling kit (Roche, Tokyo, Japan), according to
the manufacturer’s instructions. For the generation of the sense
and antisense probes of the TFF3 sequence, a sequence of human
TFF3 cDNA (base 100–359) obtained from a thyroid tissue was
subcloned into pGEM Easy plasmid.
Statistical analysis
Statistical analysis of differences between the groups was carried
out using the Mann–Whitney U-test. P’s of o0.05 were considered
significant.
RESULTS
In the second screening by real-time quantitative RT–PCR, one
sequence, F4, showed different expression levels between follicular
adenomas and carcinomas but the other 25 sequences did not
show clear differences between the two groups (Figure 2). By
sequence analysis, the cDNA amplified by F4 primer was
determined to be TFF3. The expression levels of TFF3 mRNA
were measured by real-time quantitative RT–PCR using specific
primers and a probe for the TFF3 gene and the values were divided
by the expression levels of b-actin mRNA. TFF3 mRNA was
abundantly expressed in normal thyroid tissues, adenomatous
goitres, and medullary carcinomas, whereas decreased expression
was observed in follicular adenomas, follicular carcinomas, and
especially in papillary and anaplastic carcinomas (Figure 3 and
Table 2).
A total of 48 follicular adenomas and 29 follicular carcinomas
were analysed. Five cases were oxyphilic cell tumours and eight
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scases were ‘definite’ carcinomas, which included seven widely
invasive carcinomas and one minimally invasive carcinoma with
lung metastasis. Among the other cases, six adenomas and six
carcinomas were difficult to classify by the pathologist because of
questionable pathological features, for example, insufficient
penetration into the capsule. In follicular tumours, a significant
difference in the expression levels of TFF3 mRNA was observed
between follicular adenomas and carcinomas (Figure 3). Five
oxyphilic tumours (four adenomas and one carcinoma) showed
decreased expression levels of TFF3 mRNA. All eight definite
carcinomas showed greatly decreased expression levels of TFF3
mRNA. All six questionable adenomas and three of the six
questionable carcinomas showed decreased and greatly increased
expression levels of TFF3 mRNA, respectively (Figure 4).
An in situ hybridisation study was performed to confirm that
the expression of TFF3 mRNA was restricted to thyroid follicular
cells. Strong staining of TFF mRNA in thyroid follicular cells was
observed, which indicated that the majority of TFF3 mRNA is
expressed by thyroid follicular cells but not stroma or blood cells
(Figure 5).
DISCUSSION
Since SAGE analysis does not require special equipment or
materials, it is more convenient and less expensive when compared
with DNA chips or arrays. However, one of the limitations of the
original protocol of SAGE is that the information on the gene
Table 1 Primers used in HDSS
Tag count
a
Sequence (GTAC–) FC FA Gene bank match Selected 30primer (CGCGCGT13) Result
b
F1 CTGCCGCCGCCGCC 0 61 Cellular retinoic acid-binding protein -GC B
F2 TCGGGGAGCTGCGG 1 27 No match -GC B
F3 TATTTAACTGACTA 0 18 Tumour rejection antigen (gp96) 1 (TRA1) -CT C
F4 GTGGGCCTGTCTGC 5 74 Trefoil factor 3 -CG A
F5 CAGCCGGGCCAGCA 1 13 Cell membrane glycoprotein, 110000M(r) -GC B
F6 TCCAGCGCTGGGAG 0 9 No match -GA B
F7 CGGGAGAGGCAGGT 0 9 Oxidative 3 alpha hydroxysteroid dehydrogenase -GC B
F8 CTTCCCACTGGCCT 0 8 Histone deacetylase 1 (HDAC1) -CA B
F9 CGGCCCCCGCCGCC 0 7 cDNA, 30 end (Hs.205805) -GC B
F10 CCAACGGGCCGGGG 0 7 No match -GC B
F11 ACTGCAGCCTCCAA 0 7 Interferon, alpha-inducible protein -GT B
F12 CTGGCATGGCAGCA 0 6 GSTT1 -GT C
F13 TGGGTCTGTTGGCC 0 5 SUMO-1 activating enzyme subunit 1 (SAE1) -GC B
F14 TGGGCACAGGCCGC 0 5 (Clone hKvBeta3) K+ channel beta subunit -GA B
F15 GACGAGTCGGGCCC 0 5 Actin, gamma 1 (ACTG1) -GG D
F16 CTTGCGGCCCGTGT 0 5 No match -GA B
F17 CTGCGGCCGCCTCG 0 5 cDNA DKFZp566J153 -GC D
F18 CTCAGAAGTGTGCC 0 5 No match -GC D
F19 CGATGCGTGGGCTG 0 5 TM7XN1 protein -GA C
F20 CCTGCATCACTGCC 0 5 No match -GC C
C1 TTCGCCGAGAGGGT 15 1 Cysteine-rich protein 1 (intestinal) (CRIP1) -CC B
C2 CGCCGCCGCGCCGC 12 0 No match -GG C
C3 CTGACTTGGGCATC 22 2 SNC73 protein (SNC73) -GG B
C4 CTCACGCTTATCAG 10 1 No match -CA C
C5 CCCAGACGTCTGGT 10 0 No match -CC B
C6 TTTCAACCATCTAC 6 0 No match -CC B
C7 CTTTGAACAGCAAC 6 0 Unknown mRNA -CA C
C8 CTGCTGCTCAAGCC 6 0 Clone 333H23 on chromosome 22q12.1–12.3. -GT B
C9 CGGAAGCGAGAGTG 6 0 EST(BM782041) -GG B
C10 CCGGGAGGCGGAGG 6 0 Chromosome 16 BAC clone -GA B
C11 CCAGCCCTTGTGTG 6 0 No match -GG C
C12 CACCATGCCTGGCT 6 0 cDNA, 30 end (Hs.155873) -GC B
C13 TGGTCTTCGCCTTG 5 0 No match -CA B
C14 TCTGCTGAGTGGGC 5 0 Aldehyde dehydrogenase 10 (ALDH10) -CC B
C15 TCCAGCCTGGGCTA 5 0 cDNA, 30 end (Hs.53106) -GA C
C16 CGTCGAGGTCAGTC 5 1 cDNA, 30 end (Hs.30807) -CA C
C17 CCCAAGGCCAGGCC 5 0 No match -GC B
C18 CCAGACTGCCCACC 5 0 No match -GC B
C19 CACCACTCACAGCT 5 0 Aldo-keto reductase family 7, member A2 -CG B
C20 AGGTGCCCTCTGTG 5 0 Laminin receptor 1 (67kDa, ribosomal protein SA) -AG C
aFC¼follicular carcinoma; FA¼follicular adenoma.
bA¼a positive result in the second screening; B¼a negative result in the second screening; C¼discordant results in SAGE
and RT–PCR; D¼no amplification of a single band.
489 bp
267 bp
80 bp
C2 C3 C5 C17 C18 F18 F5 F4 F2 F1
Figure 1 A representative gel image of the PCR products amplified by
the primer sets designed for the HDSS analysis. After real-time quantitative
RT–PCR analysis using the primer sets described in Table 1, the PCR
products were run on a 2% agarose gel. In this figure, all primer sets except
F18 amplified a single band.
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sexpression profiles consists of occurrences of 14-bp sequences.
This is a severe limitation, especially in the rapid second screening,
because PCR primers are hard to design. In HDSS, the modified
SAGE analysis constructs the gene expression profiles with 18-bp
tags, with which we can easily proceed to the second screening by
real-time quantitative RT–PCR. In fact, 37 of the 40 primers
designed in this study amplified the corresponding cDNA
successfully. However, in real-time RT–PCR analysis, 11 of the
37 primers set in this HDSS study showed no or discrepant
differences between the two tissues used in the SAGE analysis. This
was probably due to either: (1) the primer sets amplify different
cDNA from that detected in the SAGE analysis, or (2) real-time
RT–PCR is less sensitive than SAGE in the detection of the
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Figure 2 Representative results of the second screening by real-time
PCR. cDNAs from four follicular adenomas (closed circles) and four
follicular carcinomas (open circles) were amplified by the corresponding
primer sets, and the quantity of the PCR products was measured. C12 and
F4 showed negative and positive results, respectively.
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Figure 3 Expression levels of TFF3 mRNA relative to b-actin mRNA in
thyroid tumours. The results are shown as the mean from duplicate
determinations. N, normal thyroid tissues; MC, medullary carcinomas; AG,
adenomatous goitres; FA, follicular adenomas; FC, follicular carcinomas; PC,
papillary carcinomas; and AC, anaplastic carcinomas.
Table 2 Expression of TFF3 mRNA in thyroid tumours
Tissue Number
TFF3
mRNA/b-
actin mRNA
(mean7s.e.) Minimum Maximum
Normal thyroid 19 210.5758.6 8.4 829.3
Medullary
carcinoma
9 198.8782.5 16.9 785.0
Adenomatous
goitre
10 323.8760.7 52.6 599.2
Follicular adenoma 48 20.275.6 0.019 240.5
Follicular carcinoma 29 9.274.8 0.014 135.7
Papillary carcinoma 25 2.070.5 0.002 11.3
Anaplastic
carcinoma
5 0.270.2 0.002 1.1
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Pathological diagnosis
Figure 4 Expression levels of TFF3 mRNA relative to b-actin mRNA in
follicular tumours. The results are shown as the mean from duplicate
determinations. (1) Adenomas; (2) questionable adenomas; (3) minimally
invasive carcinomas; (4) questionable minimally invasive carcinomas; (5)
definite carcinomas; (6) oxyphilic cell adenomas; and (7) an oxyphilic cell
carcinoma.
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sdifferent expression levels of each gene, thus, differences between
those genes whose expression differs slightly can be detected by
SAGE but not by real-time RT–PCR. Among the 26 primer sets
that proceeded to the second screening, only a primer set to
amplify TFF3 cDNA showed a clear difference between adenomas
and carcinomas. It is not likely that this fact indicates the
limitation of HDSS as a tool for the rapid differential screening of
mRNA. Rather, considering the fact that no mRNAs that
distinguish follicular adenoma and carcinoma have been reported,
there is probably a rarity of differentially expressed genes between
follicular adenomas and carcinomas.
Using HDSS, we detected TFF3 as a differentially expressed gene
between follicular adenomas and carcinomas. In a recent study
using DNA arrays, Huang et al (2001)described the differential
expression of TFF3 between normal thyroid tissues and papillary
carcinomas. The trefoil factor family, which includes TFF3, is a
relatively new family of peptides that bears the three-loop trefoil
domain (Wong et al, 1999). They are mainly synthesised and
secreted by mucin-secreting epithelial cells lining the gastrointest-
inal tract and have a close association with mucins. They are highly
conserved during evolution and are resistant to heat, acid and
enzymes. The TFF peptide action is still unknown; however, their
abundant expression in various ulcerative conditions suggests an
important role in mucosal defence and repair. Even less is known
about TFF3, since it was the last to be identified. TFF3 is expressed
mainly in the goblet cells of the small and large intestine and has
recently been found abundantly in salivary glands (Devine et al,
2000). Some studies showed that immunoreactive TFF3 expression
has been detected in neoplastic human colonic mucosa, colocalis-
ing with neutral mucin production, but loss of TFF expression is
associated with tumour necrosis and advanced Dukes’ stage
(Machado et al, 1996).
The reason for the differential expression of TFF3 in follicular
adenomas and carcinomas is not clear. Normal thyroids,
adenomatous goitres and medullary carcinomas overexpress
TFF3 mRNA. As these tissues are known to produce hormones,
such as T3, T4 and calcitonin, the TFF3 peptide might play some
roles in hormone secretion in the thyroid; thus, TFF3 mRNA can
be regarded as a marker of cell differentiation.
Pathological diagnosis of follicular carcinoma is quite difficult
and it usually requires a demonstration of vascular or full-
thickness capsular invasion in a surgical specimen. In fact, in
many cases, discrepant diagnoses are made by different patholo-
gists. Further, by classification of WHO, which does not refer to
the biological characteristics of the tumour cells but only to the
minute sign of invasion, it is not surprising that a considerable
number of ‘biological’ follicular carcinomas are diagnosed as
‘pathological’ follicular adenomas. However, to what extent this
has happened is quite difficult to estimate because evident
malignant features of follicular carcinoma such as distant
metastasis often appear many years after surgery. Thus, some
kind of objective molecular criteria that distinguish benign and
malignant follicular tumours, which reflect the biological char-
acteristics of the tumour cells, are necessary for making more
correct diagnoses. Differentially expressed mRNAs between
follicular adenomas and carcinomas can be a good indicator in
such molecular-based classification.
The expression of TFF3 mRNA is decreased significantly in
follicular carcinomas compared with follicular adenomas. Eight
definite carcinomas with wide invasion or distant metastasis
showed greatly decreased expression. These results indicate that
the decreased expression of TFF3 is closely related to the
malignant features of follicular cells. Interestingly, as shown in
Figure 4, the majority of follicular adenomas with low expression
levels of TFF3 showed questionable pathological features. On the
other hand, three of the four follicular carcinomas with high
expression levels of TFF3 were pathologically questionable. These
results strongly suggest the possibility that TFF3 mRNA expression
is an objective indicator of malignancy in follicular tumours and
may be useful in diagnosing follicular tumours, which are difficult
to classify by pathological means. However, it is not possible to
determine to what extent this hypothesis is correct, and long-term
observation of the two groups, one with high and the other with
low expression of TFF3 mRNA, is needed before we can clarify the
usefulness of these molecular-based criteria. In five oxyphilic cell
tumours, regardless of pathological classification, low expression
levels of TFF3 mRNA were observed. Although analysis of a large
number of samples is needed, TFF3 mRNA expression may not be
useful for determining the malignant features of oxyphilic cell
tumours.
In our preliminary study, differentiation of follicular adenomas
from follicular carcinomas was not possible by the in situ
hybridisation study since both tumour cells showed a positive
staining of TFF3 mRNA (data not shown). These results were not
surprising, however, since even in widely invasive follicular
carcinomas, TFF3 mRNA was expressed at almost the same level
as b-actin mRNA. This fact suggests that the use of TFF3 mRNA or
peptide in the diagnosis of follicular tumours by morphological
methods, such as in situ hybridisation or immunohistochemistry,
might be difficult, although in some cases, modifications of the
methods to reduce the sensitivity might work.
Several trials have been performed to diagnose follicular
carcinomas preoperatively, but unfortunately most of them were
A
B
Figure 5 In situ hybridisation study using an antisense probe for TFF3
mRNA ( 100). (A) A follicular adenoma with abundant expression of
TFF mRNA; and (B) a section from the same tumour stained with a sense
probe as a negative control.
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usefulness of immunohistochemical study of galectin-3 for the
diagnosis of thyroid follicular carcinoma (Bartolazzi et al, 2001).
However, in another study, no significant differences were
observed between follicular carcinomas and adenomas by quanti-
tative measurement of galectin-3 mRNA (Bernet et al, 2002). Zeiger
et al. measured the expression levels of telomerase reverse
transcriptase (hTERT) in follicular tumours and showed that this
method was to some extent useful in diagnosing follicular
carcinomas, although they also described interference due to
contamination by lymphocytes, which expressed a considerable
copy number of hTERT mRNA (Zeiger et al, 1999). Kroll et al
reported some promising data in which PAX8-PPARg1 fusion
mRNA and protein were detected in 60% of thyroid follicular
carcinomas but not in follicular adenomas, papillary carcinomas,
or multinodular hyperplasias. However, because their study
employed only a small number of follicular carcinomas, additional
examination is necessary (Kroll et al, 2000). As TFF3 mRNA is
abundantly expressed in thyroid tumours, measurement of the
copy number in FNAB samples may not be difficult. Thus, when an
accurate system to measure the quantity of TFF3 mRNA is
established, it may be possible to distinguish follicular adenomas
and carcinomas preoperatively.
ACKNOWLEDGEMENTS
This research was partially supported by the Ministry of
Education, Culture, Sports, Science and Technology of Japan,
Grants-in-Aid for Scientific Research on Priority Areas,
2001, No. 13216068 and Scientific Research B, 2001-2, No.
13557227. We thank Hiromi Takarada for technical assistance,
Dr Toru Wakatsuki for providing the PROGENEX software,
and the staff of Kuma Hospital for correcting the clinical
samples.
REFERENCES
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A,
Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R,
Larsson O (2001) Application of an immunodiagnostic method for
improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:
1644–1650
Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman
KD, Burch HB, Ringel MD (2002) Determination of galectin-3 messenger
ribonucleic acid overexpression in papillary thyroid cancer by quanti-
tative reverse transcription-polymerase chain reaction. J Clin Endocrinol
Metab 87: 4792–4796
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by
acid guanidinium thiocyanate–phenol–chloroform extraction. Anal
Biochem 162: 156–159
Cooper DS, Schneyer CR (1990) Follicular and Hurthle cell carcinoma of
the thyroid. Endocrinol Metab Clin N Am 19: 577–591
Devine DA, High AS, Owen PJ, Poulsom R, Bonass WA (2000) Trefoil factor
expression in normal and diseased human salivary glands. Hum Pathol
31: 509–515
Hamburger JI (1994) Diagnosis of thyroid nodules by fine needle biopsy:
use and abuse. J Clin Endocrinol Metab 79: 335–339
Hasegawa Y, Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K,
Amino N (2002) Decreased expression of glutathione peroxidase mRNA
in thyroid anaplastic carcinoma. Cancer Lett 182: 69–74
Hauser F, Poulsom R, Chinery R, Rogers LA, Hanby AM, Wright NA,
Hoffmann W (1993) hP1.B, a human P-domain peptide homologous with
rat intestinal trefoil factor, is expressed also in the ulcer-associated cell
lineage and the uterus. Proc Natl Acad Sci USA 90: 6961–6965
Hedinger C, Williams ED, Sobin LH (1989) The WHO histological
classification of thyroid tumors: a commentary on the second edition.
Cancer 63: 908–911
Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K,
LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A
(2001) Gene expression in papillary thyroid carcinoma reveals highly
consistent profiles. Proc Natl Acad Sci USA 98: 15044–15049
Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM,
Fletcher JA (2000) PAX8-PPARgamma1 fusion oncogene in human
thyroid carcinoma. Science 289: 1357–1360
Machado JC, Carneiro F, Ribeiro P, Blin N, Sobrinho-Simoes M (1996) pS2
protein expression in gastric carcinoma. An immunohistochemical and
immunoradiometric study. Eur J Cancer 32A: 1585–1590
Ponte P, Ng SY, Engel J, Gunning P, Kedes L (1984) Evolutionary
conservation in the untranslated regions of actin mRNAs: DNA sequence
of a human beta-actin cDNA. Nucleic Acids Res 12: 1687–1696
Ryo A, Kondoh N, Wakatsuki T, Hada A, Yamamoto N, Yamamoto M
(2000) A modified serial analysis of gene expression that generates longer
sequence tags by nonpalindromic cohesive linker ligation. Anal Biochem
277: 160–162
Takano T, Amino N (2002) Cancer-specific mRNAs in thyroid carcinomas:
detection, use, and their implication in thyroid carcinogenesis. Endocr J
49: 97–107
Takano T, Hasegawa Y, Matsuzuka F, Miyauchi A, Yoshida H, Higashiyama
T, Kuma K, Amino N (2000b) Gene expression profiles in thyroid
carcinomas. Br J Cancer 83: 1495–1502
Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K,
Amino N (2001) Overexpression of kalpha1 tubulin mRNA in thyroid
anaplastic carcinoma. Cancer Lett 168: 51–55
Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K,
Amino N (2002a) Quantitative analysis of thymosin beta-10 messenger
RNA in thyroid carcinomas. Jpn J Clin Oncol 32: 229–232
Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K,
Hayashi N, Nakamori S, Amino N (2002b) Quantitative analysis of
osteonectin mRNA in thyroid carcinomas. Endocr J 49: 511–516
Takano T, Matsuzuka F, Miyauchi A, Yokozawa T, Liu G, Morita S, Kuma
K, Amino N (1998b) Restricted expression of oncofetal fibronectin
mRNA in thyroid papillary and anaplastic carcinoma: an in situ
hybridization study. Br J Cancer 78: 221–224
Takano T, Miyauchi A, Matsuzuka F, Liu G, Higashiyama T, Yokozawa T,
Kuma K, Amino N (1999a) Preoperative diagnosis of medullary thyroid
carcinoma by RT–PCR using RNA extracted from leftover cells within a
needle used for fine needle aspiration biopsy. J Clin Endocrinol Metab 84:
951–955
Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N
(2000a) Diagnosis of thyroid malignant lymphoma by reverse transcrip-
tion-polymerase chain reaction detecting the monoclonality of immu-
noglobulin heavy chain messenger ribonucleic acid. J Clin Endocrinol
Metab 85: 671–675
Takano T, Miyauchi A, Yokozawa T, Matsuzuka F, Liu G, Higashiyama T,
Morita S, Kuma K, Amino N (1998a) Accurate and objective preoperative
diagnosis of thyroid papillary carcinomas by reverse transcription-PCR
detection of oncofetal fibronectin messenger RNA in fine-needle
aspiration biopsies. Cancer Res 58: 4913–4917
Takano T, Miyauchi A, Yokozawa T, Matsuzuka F, Maeda I, Kuma K,
Amino N (1999b) Preoperative diagnosis of thyroid papillary and
anaplastic carcinomas by real-time quantitative reverse transcription-
polymerase chain reaction of oncofetal fibronectin messenger RNA.
Cancer Res 59: 4542–4545
Takano T, Sumizaki H, Amino N (1997) Detection of CD44 variants in fine
needle aspiration biopsies of thyroid tumor by RT–PCR. J Exp Clin
Cancer Res 16: 267–271
Velculescu VE, Zhang L, Vogelstein B, Kinzler KW (1995) Serial analysis of
gene expression. Science 270: 484–487
Wong WM, Poulsom R, Wright NA (1999) Trefoil peptides. Gut 44: 890–
895
Yokozawa T, Miyauchi A, Kuma K, Sugawara M (1995) Accurate and
simple method of diagnosing thyroid nodules the modified technique of
ultrasound-guided fine needle aspiration biopsy. Thyroid 5: 141–145
Zeiger MA, Smallridge RC, Clark DP, Liang CK, Carty SE, Watson CG,
Udelsman R, Saji M (1999) Human telomerase reverse transcriptase
(hTERT) gene expression in FNA samples from thyroid neoplasms.
Surgery 126: 1195–1198
TFF3 mRNA in thyroid follicular tumours
T Takano et al
1605
British Journal of Cancer (2004) 90(8), 1600–1605 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s